Kornimate/medical-research-clean huggingface dataset:
conscious movement processing, postural stability and muscle efficiency in older adults

Conditions: Fall Injury; Postural; Defect; Old Age; Debility

Summary: this study aims to address critical knowledge gaps by investigating the effects of trait conscious movement processing propensity on real-time (state) conscious movement processing propensity, postural stability, and muscle efficiency in older adults at risk of falling in hong kong with high and low trait conscious movement processing propensities, while standing in a challenging environment with different levels of standing task difficulties. the study results would contribute to our scientific understanding of the mechanisms of conscious movement processing in older adults while maintaining standing balance in a challenging environment. it could inform the follow-up investigations for the development of the most appropriate psychomotor standing balance re-education intervention in rehabilitation so as to mitigate the effect of conscious movement processing and the risk of falling in older adults. the findings from the proposed research could ultimately help improve the outcome of fall rehabilitation programmes and reduce the impact of falls in the older adults in hong kong.


Eligibility criteria:
inclusion criteria: * 65 years old or above; * able to stand independently without a walking aid. exclusion criteria: * a history of any major cerebrovascular and/or neurological disorders (e.g., stroke, parkinson's disease); * a history of a major fall event within the past year; * the existence of an unstable medical or mobility condition that could affect safety in this study; * a score of 23/30 or below in the chinese version of mini-mental state examination (mmse-c); * a static visual acuity poorer than 20/40 vision (examined by the tumbling-e eye chart).

Keywords: older adults in hong kong conscious movement processing postural stability muscle efficiency attentional focus
a prospective assessment of opioid utilization post-operatively in sports orthopaedic surgeries

Conditions: Narcotic Use; Postoperative Pain; Narcotic Abuse; Opioid Use; Opioid Abuse, Uncomplicated; Opioids; Harmful Use; Analgesic Drug Dependence; Orthopedic Disorder

Summary: there was a study titled "a prospective evaluation of opioid utilization after upper extremity surgical procedures: identifying consumption patterns and determining prescribing guidelines" by dr. matzon and team from thomas jefferson university that came up with a simple set of opioid guidelines post-surgically. these guidelines are helping to guide surgeon's prescribing patterns and ideally limit the number of prescribed pain medicines. we plan to identify typical narcotic analgesic usage post sports orthopaedic surgery. we hope to identify the number of narcotic pain pills to prescribe to patients undergoing orthopaedic sports surgery in the future.

1, consent patients undergoing sports orthopaedic surgery in clinic or in pre-operative holding area and also administer first questionnaire, opioid risk tool, and pain catastrophizing scale(research) 2. sports orthopaedic surgery (standard of care) 3. post-op pain control regimen (standard of care) 4. call or email patient with questionnaire every day for a week followed by weekly for 7 more weeks. the children's questionnaire will be child specific and the parent will assist the child. will also use a picture of wong-baker faces to help children identify where their pain scale is which will be given to the patient the same day that the consent is obtained to use at home(research). questionnaire should take less than 5 minutes and will include questions about how well their pain is controlled, how many analgesic medications they have taken, and if they have tried anything else for pain. (research) 5. patient will continue to go to post-operative appointments as scheduled. (standard of care) 6. will store the data from the phone calls on the secured t drive. (research)

Eligibility criteria:
inclusion criteria: * analgesics prescribed to patient patients that have undergone orthopaedic sports surgeries that dr. kaar and dr. kim performed with some of the examples being: acromioplasty rotator cuff repair labral repair proximal humerus repair versus arthroplasty elbow instability repair elbow arthroplasty hip arthroscopy hip cam lesion repair knee arthroscopy knee ligament repair knee meniscus repair achilles tendon repair cartilage preserving procedures exclusion criteria: mental retardation inmates non-english speaking pregnant on-call trauma cases
the associations of microribonucleic acid gene polymorphisms with the risk of ulcerative colitis

Conditions: Colitis, Ulcerative

Summary: from january 2020 to december 2024, diagnosed ulcerative colitis(uc) patients and gender- and age-matched normal controls were enrolled from the department of gastroenterology, the second affiliated hospital of wenzhou medical university. our aim is to investigate the associations of microribonucleic acid(mirna) gene polymorphisms with the risk and clinicopathological characteristics of uc, and to analyze the effects of mirnas gene variations on the clinical response of vedolizumab(vdz) treatment in uc patients.

from january 2020 to december 2024, diagnosed uc patients and gender- and age-matched normal controls were enrolled from the department of gastroenterology, the second affiliated hospital of wenzhou medical university. genotypes of mirnas were determined by multiplex polymerase chain reaction-ligase detection reaction technique. chi-square test and unconditional logistic regression model were used to analyze the difference in distribution of mirnas gene polymorphisms between uc group and normal control group, as well as the effects of mirnas gene variations on the clinicopathological characteristics and 14-week clinical response to vdz treatment of uc patients.

Eligibility criteria:
inclusion criteria: * diagnosed uc based on comprehensive clinical, colonoscopy, histopathological, laboratory, and radiographic examination results exclusion criteria: * rheumatoid arthritis, systemic lupus erythematosus, intestinal tuberculosis, ischemic enteritis, radiation enteritis, tumors, etc.
the research value of multi-omics and multi-modal information in the diagnosis and treatment of urinary system tumors

Conditions: Urinary System Carcinoma

Summary: obtain puncture or surgically removed tumor tissue samples from patients with urinary tract tumors and perform rna-sequencing, single-cell rna-sequence, spatial transcriptomics, proteomics, and intratumoral microbiome.


Eligibility criteria:
inclusion criteria: 1. patients were treated for bladder cancer, kidney cancer, and prostate cancer in wuhan union hospital from january 2024 to january 2026; 2. aged \> 18 years old; 3. urinalysis, urine exfoliated cells, ultrasound, ct, and mr examinations indicated the above tumors; 4. tissue biopsy pathological examination confirmed the diagnosis of the above tumors. exclusion criteria: 1. poor image quality; 2. incomplete clinical data or loss of follow-up; 3. presence of another primary malignant tumor other than urinary tract tumor; 4. unclear pathological diagnosis
impact of a memory group for older adults reporting memory difficulties

Conditions: Mild Cognitive Impairment; Alzheimer's Disease

Summary: aims: to evaluate the efficacy of a brief intensive intervention for persons with mild cognitive impairment, assisted by family members or friends. to equip persons with mild cognitive impairment with specific skills to prevent memory failures and improve the capacity of patients and families to cope with everyday memory difficulties.

participants: the sample will consist of 60 families who have a family member reporting memory loss and who have recently been assessed within the cognitive dementia and memory service (cdams). participants will include patients and a family member / close friend. the potential patient participants must have received a diagnosis of mild cognitive impairment following a comprehensive clinical assessment. they must also be english speakers, live in the community, have no evidence of significant visual or auditory impairment, and have no history of diagnosed alcohol or drug abuse or major psychological disorder. potential family / friend participants are expected to be spouses or adult children. brief description: patients and their carers will be assigned to either a 'brief intervention group' or a 'no intervention group'. over 5 1 1/2 -hour weekly sessions, the brief intervention group will be taught a memory skills program which emphasises practical strategies for dealing with everyday memory problems. interactive group discussion and 'take home' exercises are also included. the no intervention group will serve as a control group, and will receive only their usual care from the the memory clinic. at the completion of the study, the brief intervention will be offered to those in the no intervention group. all participants will complete questionnaires about knowledge of memory techniques, common memory and behaviour problems and emotional health at pre-intervention, post-intervention and after a 3-month follow-up. methods of data analysis: outcome evaluation will be monitored by neuropsychological assessments of memory performance, and subjective self-reports. a 2 x 3 multivariate analysis of variance (manova) will be used to assess differences on the experimental measures between groups (brief intervention, no intervention) across repeated assessment phases (pre-intervention, post-intervention, 3-month follow-up).

Eligibility criteria:
inclusion criteria: participant presents with memory complaint objective memory impairment on neuropsychological tests normal general cognitive function adequate activities of daily living fails to reach criterion for clinical dementia according to nincds-adrda guidelines living in the community absence of significant visual or auditory impairment english speaker - exclusion criteria: -

Keywords: alzheimer's disease mild cognitive impairment memory intervention strategy use memory group
ex vivo 3d-ultrasound for oropharyngeal cancer

Conditions: Oropharyngeal Squamous Cell Carcinoma

Summary: patients with biopsy-verified oropharyngeal squamous cell carcinomas treated with transoral robotic surgery are included. immediately post-operatively, freshly resected specimens are examined with ex vivo 3d ultrasound (us). ex vivo 3d us will be used to match us slices of the specimen with corresponding histopathology slices. the us slices will be reviewed by a panel of head and neck surgeons blinded to histopathology. the primary aim is to explore perioperative ex vivo 3d us for oropharyngeal tumor detection, delineation from normal tissue, tumor size and volume, and margin assessment.

the purpose of the study is to determine the accuracy of ex vivo 3d ultrasound (us) for detecting and delineating tumor tissue of the tonsils and base of tongue post-operatively. this is a quick technique that may provide valuable information for the surgeon that can potentially improve treatment outcomes. placing the surgical specimen in a water bath allows for an us swipe to be performed without compressing the specimen. this reduces the deformation of the specimen by removing the pressure from conventional us scanning. a video clip can be captured by swiping across the specimen in the water bath. by motorizing this motion, the video can be converted into a 3d volume due to the known number of video frames and a constant swiping speed. we will correlate the ex vivo 3d us scans to histopathology for the following analyses: * four surgeons blinded to histopathology will rate each included case in terms of tumor visibility on ex vivo 3d us scans. if visible, the surgeons will mark the tumor and the healthy tissue. * tumor and margins will be correlated to histopathology pre- and post-formalin fixation on a subset of cases to explore the proportion of tissue shrinkage from formalin fixation.

Eligibility criteria:
inclusion criteria: * patients surgically treated with transoral robotic surgery for oropharyngeal squamous cell carcinoma. exclusion criteria: * patients from the qolati trial (nct04124198)
pharmacologic treatment of myocardial ischemia detected by intracoronary ecg

Conditions: Coronary Ischemia

Summary: after pci searching for target lesion ischemia with intracoronary ecg will be performed and if found it will be treated pharmacologically

the study will include patients with coronary lesions and pci. it will include patients with stable or unstable angina, without elevated hs-tnt. pci will be performed and monitoring of intracoronary st elevation. any dissection or acute vessel closure will be promptly treated with balloon or stenting. although there could be good angiographic result sometimes ischemia could be detected in the treated region by means of intracoronary ecg st elevation above 1mm. this study aims to tackle this issue with randomization of the patients into three possible treatments - intracoronary adenosine, iib/iiia inhibitors or nitroglycerine alone - intracoronary st segment will be searched for reverse or residual ischemia after the pharmacologic bolus. the intracoronary electrocardiography (i.c. ecg) is a very sensitive method for ischemia detection. the i.c. ecg reacts earlier on ischemia; the changes are much more prominent and easy to register. the wire tip could be positioned directly in different regions and thus to "map" regional ischemia. in most of the studies and from our own observations became evident that when surface ecg do not react the i.c. ecg demonstrates significant changes in st-segment and qrs complex. moreover, the registration of i.c. ecg is very cheap and needs only an adapter connecting coronary wire end and ecg. an i.c. ecg also can differentiate residual ischemic changes in distal main vessel and side branch as sources of prolonged ischemia, respectively - source of periprocedural myonecrosis. once good angiographic result is obtained after stenting there could be different reasons for ischemia in the treated region - microembolic debris or coronary microvascular spasm.

Eligibility criteria:
inclusion criteria: * subject at least 18 years of age. * target lesion(s) located in a native coronary artery with diameter of ≥ 2.5 mm and ≤ 4.5 mm. if there is side branch lesion(s) located in a native coronary artery with diameter of ≥ 2.0 mm. * target lesion(s) amenable for pci with balloon angioplasty of the side branch. exclusion criteria: * subjects with significant st-t change (≥ 1mm). * non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment). * subjects who refuse to give informed consent. * subjects with the following angiographic characteristics: left main coronary artery stenosis, total occlusion target lesion, lesion of interest located at infarct-related artery. * subjects with lvef \< 30%. * subjects with moderate or severe degree valvular heart disease or primary cardiomyopathy. * lbbb, rbbb, atrial fibrillation/flutter with no identifiable isoelectric line.
an extension study to assess long-term safety of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy (attr-cm)

Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Summary: the purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with attr-cm.

this is a multicenter, open-label, phase 3 study in up to approximately 1400 participants. eligible participants will receive eplontersen once every 4 weeks for up to 36 months or 6 months after eplontersen is approved and available in the site's country, whichever occurs first. participants will also receive daily supplemental doses of the recommended daily allowance (rda) of vitamin a. this study will consist of the following periods: less than or equal to (≤) 10-week screening assessment period, up to 36-month treatment period, and up to 6-month post-treatment evaluation period.

Eligibility criteria:
inclusion criteria: 1. satisfactory completion of treatment period and the end of treatment visit of the index study (ion-682884-cs2) or diagnosis of attr-cm and satisfactory participation on isis 420915- cs101 study as judged by the investigator and sponsor. 2. investigator is willing to treat the participant with open-label eplontersen. 3. willingness to adhere to vitamin a supplementation per protocol. exclusion criteria: 1. permanently discontinued study drug administration while participating in the index study (ion 682884-cs2) or ist (isis 420915-cs101 study). 2. have any new condition or worsening of an existing condition that in the opinion of the investigator or sponsor would make the participant unsuitable for enrolment, or which could interfere with the participant participating in or completing the study, including the need for treatment with medications disallowed in the index study.

Keywords: amyloidosis
gatifloxacin versus ceftriaxone in the treatment of enteric fever

Conditions: Enteric Fever; Typhoid Fever

Summary: the investigators aim to compare two antibiotic treatments for enteric (typhoid) fever. three hundred patients at patan hospital will be enrolled in the study. patients will be assigned to one of the two treatments by chance and followed for 6 months. the two treatment groups will be compared to see which treatment is more likely to make the patient better.

with the study hypothesis that gatifloxacin is superior to ceftriaxone in terms of treatment failure in patients with enteric fever, a comparative study will be conducted at patan hospital. 300 patients who are diagnosed with enteric fever will be enrolled into the study. the patients will be randomized to one of two groups. one group will receive treatment with gatifloxacin for 7 days, and the other with ceftriaxone. the patients will be followed during the treatment courses and at several points of 6 months after initial presentation. the endpoints then will be compared between two groups.

Eligibility criteria:
inclusion criteria: * suspected or culture proven enteric fever * \>= 2 \<= 45 years of age * fever \>= 38°c for \>= 4 days * informed consent to participate in the study exclusion criteria: * pregnancy * obtundation * shock * visible jaundice * presence of signs of gastrointestinal bleeding * evidence of severe disease * diabetes * history of hypersensitivity to either of the trial drugs * known previous treatment with a quinolone antibiotic or 3rd generation cephalosporin or macrolide within one week of hospital admission.

Keywords: gatifloxacin ceftriaxone enteric fever typhoid fever
remdesivir for severely ill inpatients with covid-19 (an activ-3b/tesico treatment trial)

Conditions: Covid19

Summary: this study looks at the safety and effectiveness of remdesivir in treating covid-19 in people who have been hospitalized with the infection and who have acute respiratory failure. participants in the study will be treated with remdesivir plus current standard of care (soc), or with placebo plus current soc.

this is a treatment trial of the activ-3b/tesico master protocol (nct04843761) to evaluate the safety and efficacy of remdesivir at improving outcomes for patients with acute respiratory failure related to covid-19. this protocol will be adaptive, randomized, blinded and initially placebo-controlled. participants will receive standard of care (soc) treatment as part of the protocol. this protocol will be conducted in up to several hundred clinical sites. participating sites are affiliated with networks funded by the united states national institutes of health (nih) and the us department of veterans affairs. the protocol is for a phase 3 study. participants will be followed for 90 days following randomization for the primary endpoint and most secondary endpoints. selected secondary endpoints will be measured at 180 days. this study is planned to provide 80% power to detect an odds ratio of 1.5 for improvement in recovery status at day 90 for remdesivir versus placebo with use of the ordinal outcome. the planned sample size is 320 participants. sample size may be re-estimated before enrollment is complete based on an assessment of whether the pooled proportions of the outcome are still consistent with adequate power for the hypothesized difference measured by the odds ratio. randomization will be stratified by study site pharmacy and by receipt of invasive mechanical ventilation, or ecmo (extracorporeal membrane oxygenation) at enrollment. other agent-specific stratification factors may be considered. an independent data and safety monitoring board (dsmb) will review interim safety and efficacy data at least monthly. pre-specified guidelines will be established to recommend early stopping of the trial for evidence of harm or substantial efficacy. the dsmb may recommend discontinuation of an investigational agent if the risks are judged to outweigh the benefits.

Eligibility criteria:
inclusion criteria: refer to the master protocol (nct04843761) exclusion criteria: refer to the master protocol (nct04843761) additional exclusion criteria: * prior receipt of any dose of remdesivir during the present illness * gfr (glomerular filtration rate) \< 30 ml/min and not receiving dialysis * alt (alanine aminotransferase) or ast (aspartate aminotransferase) \> 10 times upper limit of normal * unwillingness to commit to avoid sex that may result in pregnancy for at least 7 days after completion of remdesivir vs. placebo

Keywords: covid-19 covid 19 coronaviridae infections coronavirus infections rna virus infections virus diseases nidovirales infections sars-cov-2 sars coronavirus activ-3 activ3
trimetazidine efficacy in attenuating paclitaxel-induced peripheral neuropathy

Conditions: Peripheral Neuropathy Due to Chemotherapy

Summary: this proof-of-concept study evaluated the effect of trimetazidine on the incidence of paclitaxel-induced peripheral neuropathy in patients with breast cancer.

chemotherapy-induced peripheral neuropathy (cipn) is a major adverse effect of many commonly used chemotherapeutic agents that greatly affect patient quality of life. paclitaxel (ptx), one of the main neurotoxic classes of anticancer drugs, is used to treat several types of solid tumors, including breast cancer. development of ptx-induced peripheral neuropathy (pipn) during cancer treatment requires dose reduction limiting its clinical benefits. the only currently recognized prophylactic measure for chemotherapy-induced peripheral neuropathy (cipn) is monitoring for pre-existing neuropathies and then the early detection of clinical symptoms of neuropathy in subjects undergoing neurotoxic chemotherapy treatment. preclinical data has shown that the neuroprotective effect of trimetazidine (tmz) can attenuate pipn. tmz has preclinical evidence about its preventive capacity against peripheral neuropathy. which represents a possible prophylactic strategy for attenuating pipn. tmz is commercially available in various preparations that are relatively affordable and well-tolerated, making it a valid candidate for clinical evaluation.

Eligibility criteria:
inclusion criteria: * breast cancer patients who will receive paclitaxel. * eastern cooperative oncology group (ecog) performance status from 0 to 2. * adequate bone marrow function (white blood count ≥4,000/mm3, platelet count≥100,000/mm3), liver function (serum total bilirubin \<1.5 mg/dl), renal function (creatinine \< 1.5 mg/dl). exclusion criteria: * patients with signs and symptoms of clinical neuropathy at baseline. * patients with diabetes mellitus, alcoholic disease, heart failure, pregnant or lactating women. * patients receiving vitamin/ supplementation drugs that interfere with the study intervention. * patients with contraindications to trimetazidine including parkinson's disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders.

Keywords: paclitaxel trimetazidine quality of life nerve growth factor peripheral neuropathy